Table 1.
Patient demographic and tumor characteristics of trimodality eligible patients with locally advanced esophageal adenocarcinoma, according to treatment groupa
| Characteristic | Chemoradiation and Surgery (n=114) | Definitive Chemoradiation (n=29) |
|---|---|---|
| Sex—no. (%) | ||
| Male | 108 (95) | 26 (90) |
| Female | 6 (5) | 3 (10) |
| Age*** | ||
| Median | 60 | 70 |
| Range | 27–78 | 48–83 |
| Race/Ethnicity—no. (%) | ||
| White | 103 (90) | 26 (90) |
| Non-White | 11 (10) | 3 (10) |
| Tumor Location—no. (%) | ||
| Upper/middle | 1 (0) | 0 (0) |
| Lower/GEJ | 113 (99) | 29 (100) |
| Tumor Length—cm | ||
| Median | 5 | 6 |
| Range | 2–16 | 2–13 |
| Tumor Grade—no. (%) | ||
| Well/Moderately Differentiated | 40 (35) | 12 (41) |
| Poorly Differentiated | 74 (65) | 17 (59) |
| CXRT Sequence—no. (%) | ||
| Chemo/XRT | 48 (42) | 15 (52) |
| Chemo→Chemo/XRT | 66 (58) | 14 (48) |
| XRT Dose—no. (%) *** | ||
| <50.4 Gyb | 43 (38) | 2 (7) |
| 50.4 Gy | 71 (62) | 27 (93) |
| Post-Treatment Local SUV—no. (%) | ||
| <3.45 | 32 (29) | 7 (29) |
| 3.45–8.75 | 69 (63) | 13 (54) |
| ≥8.75 | 8 (7) | 4 (17) |
| missingc | 5 | 5 |
| Charlson Comorbidity Score—no. (%) | ||
| 0 | 78 (68) | 19 (66) |
| 1 | 31 (33) | 6 (21) |
| ≥2 | 5 (4) | 4 (14) |
| Surgical technique—no. (%) | ||
| Right transthoracic (Ivor Lewis) | 74 (65) | |
| Transhiatal | 11 (10) | |
| Total (three field technique) | 11 (10) | |
| Minimally invasive | 18 (16) | |
NOTE: GEJ = gastroesophageal junction; CXRT = chemoradiation; Chemo = chemotherapy; XRT = radiation; Gy = gray; SUV = standard uptake value
*
for p < 0.05,
**
for p < 0.01, and
***
for p < 0.001
a
Percentages may not add up to 100 because of rounding
b
Patients treated with <50.4 Gy typically received 45 Gy
c
Categorical variable cut-off for post-treatment SUV determined with recursive partitioning
d
Missing values not included in χ2 significance test